Update in Endocrinology
Authors: Leonard Wartofsky
Journal: Annals of Internal Medicine (2005)

Updates1 November 2005Update in EndocrinologyLeonard Wartofsky, MDLeonard Wartofsky, MDFrom Washington Hospital Center, Washington, DC.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-9-200511010-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This Update in endocrinology represents a critical examination of articles selected from more than 25 peer-reviewed journals from the fields of endocrinology and general internal medicine. Criteria for selection included both the importance of the observations and their applicability to clinical practice today. The articles are broadly grouped into various areas of endocrinology.Diabetes MellitusMyocardial Perfusion Imaging Should Be Considered To Detect Silent Coronary Artery Disease in Diabetic Patients Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004;27:1954-61. [PMID: 15277423]American Diabetes Association (ADA) guidelines (1) ...References1. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care. 1998;21:1551-9. [PMID: 9727908] CrossrefMedlineGoogle Scholar2. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol. 2002;90:827-32. [PMID: 12372568] CrossrefMedlineGoogle Scholar3. Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med. 2004;164:1925-31. [PMID: 15451769] CrossrefMedlineGoogle Scholar4. Haas RM, Hoffman AR. Treatment of diabetic ketoacidosis: should mode of insulin administration dictate use of intensive care facilities? [Editorial]. Am J Med. 2004;117:357-8. [PMID: 15336586] CrossrefMedlineGoogle Scholar5. Gerstein HC. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor [Editorial]. Ann Intern Med. 2004;141:475-6. [PMID: 15381522] LinkGoogle Scholar6. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-31. [PMID: 15381515] LinkGoogle Scholar7. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-30. [PMID: 11897280] CrossrefMedlineGoogle Scholar8. Ahren B, Landin-Olsson M, Jansson P-A, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078-84. [PMID: 15126524] CrossrefMedlineGoogle Scholar9. Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol. 2000;35:1554-9. [PMID: 10807460] CrossrefMedlineGoogle Scholar10. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J. 2003;146:5. [PMID: 12891212] CrossrefMedlineGoogle Scholar11. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-51. [PMID: 15516697] CrossrefMedlineGoogle Scholar12. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58:762-9. [PMID: 10916100] CrossrefMedlineGoogle Scholar13. Phoojaroenchanachai M, Sriussadaporn S, Peerapatdit T, Vannasaeng S, Nitiyanant W, Boonnamsiri V, et al. Effect of maternal hyperthyroidism during late pregnancy on the risk of neonatal low birth weight. Clin Endocrinol (Oxf). 2001;54:365-70. [PMID: 11298089] CrossrefMedlineGoogle Scholar14. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996;101:482-7. [PMID: 8948271] CrossrefMedlineGoogle Scholar15. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid. 1997;7:891-6. [PMID: 9459633] CrossrefMedlineGoogle Scholar16. Walsh JP, Shiels L, Lim EM, Bhagat CI, Ward LC, Stuckey BG, et al. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized, controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab. 2003;88:4543-50. [PMID: 14557419] CrossrefMedlineGoogle Scholar17. Wartofsky L. Combined levotriiodothyronine and levothyroxine therapy for hypothyroidism: are we a step closer to the magic formula? [Editorial]. Thyroid. 2004;14:247-8. [PMID: 15142357] CrossrefMedlineGoogle Scholar18. Ayala A, Wartofsky L. The case for more aggressive screening and treatment of mild thyroid failure. Cleve Clin J Med. 2002;69:313-20. [PMID: 11996201] CrossrefMedlineGoogle Scholar19. Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Virdis A, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab. 2004;89:2099-106. [PMID: 15126526] CrossrefMedlineGoogle Scholar20. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-38. [PMID: 14722150] CrossrefMedlineGoogle Scholar21. Toft A. Increased levothyroxine requirements in pregnancy—why, when, and how much? [Editorial]. N Engl J Med. 2004;351:292-4. [PMID: 15254288] CrossrefMedlineGoogle Scholar22. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341:549-55. [PMID: 10451459] CrossrefMedlineGoogle Scholar23. Calhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96. [PMID: 15325833] CrossrefMedlineGoogle Scholar24. Snow V, Aronson MD, Hornake, ER, Mottur-Pilson C, Weiss KB; the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004;140:644-9. [PMID: 15096336] LinkGoogle Scholar25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. [PMID: 12114036] CrossrefMedlineGoogle Scholar26. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease—is it time to shift our goals? [Editorial]. N Engl J Med. 2005;352:1483-4. [PMID: 15755764] CrossrefMedlineGoogle Scholar27. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. [PMID: 15007110] CrossrefMedlineGoogle Scholar28. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. [PMID: 15755765] CrossrefMedlineGoogle Scholar29. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med. 2003;163:669-76. [PMID: 12639199] CrossrefMedlineGoogle Scholar30. Lemiengre M, van Driel M, Chevalier P, De Meyere M, Christiaens T. New analyses of Heart Protection Study [Letter]. Lancet. 2004;363:1827-8; author reply 1828. [PMID: 15172789] Google Scholar31. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R, et al. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20, 536 individuals. Lancet. 2005;365:1779-85. [PMID: 15910950] CrossrefMedlineGoogle Scholar32. Clark LT. Optimizing lipid lowering in patients at risk. Clin Cardiol. 2004;27:III22-6. [PMID: 15239488] CrossrefMedlineGoogle Scholar33. Turley SD. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin Cardiol. 2004;27:III16-21. [PMID: 15239487] CrossrefMedlineGoogle Scholar34. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487-94. [PMID: 15194018] CrossrefMedlineGoogle Scholar35. Feldman T, Koren M, Insull W, McKenney J, Schrott H, Lewin A, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004;93:1481-6. [PMID: 15194017] CrossrefMedlineGoogle Scholar36. Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004;58:653-8. [PMID: 15311720] CrossrefMedlineGoogle Scholar37. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167:512-20. [PMID: 12426230] CrossrefMedlineGoogle Scholar38. Luce JM. Physicians should administer low-dose corticosteroids selectively to septic patients until an ongoing trial is completed [Editorial]. Ann Intern Med. 2004;141:70-2. [PMID: 15238374] LinkGoogle Scholar39. Cooper MJS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348:727-34. [PMID: 12594318] CrossrefMedlineGoogle Scholar40. Loriaux L. Glucocorticoid therapy in the intensive care unit. N Engl J Med. 2004;350:1601-2. [PMID: 15084691] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Washington Hospital Center, Washington, DC.Disclosures: None disclosed.Corresponding Author: Leonard Wartofsky, MD, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDiseases of ThyroidDermatologic aspects of thyroid disease 1 November 2005Volume 143, Issue 9Page: 673-682KeywordsBlood plasmaCortisolHypothyroidismPregnancyStatinsThyroid hormonesThyroid-stimulating hormoneThyroxine ePublished: 1 November 2005 Issue Published: 1 November 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...